Jones Brian A, Beamer Maria, Ahmed Salahuddin
Department of Pharmacology, College of Pharmacy, University of Toledo, OH, USA.
Mol Interv. 2010 Oct;10(5):263-70. doi: 10.1124/mi.10.5.3.
A better understanding of the immunological processes governed by cytokines and chemokines has shaped our approach to the design of therapeutics for diseases such as rheumatoid arthritis (RA), atherosclerosis, and other inflammatory disorders. The discovery of chemokines and their receptors as integral components and regulators of inflammation has dramatically contributed to advances in treating these disease states. Among the different classes of chemokines, fractalkine/CX3CL1, with its unique functional and structural characteristics, has been found to participate in inflammation. This viewpoint summarizes the emerging role of fractalkine/CX3CL1 from the historical, functional, and clinical perspective and provides evidence to validate it as a potential therapeutic target in cardiovascular disease, rheumatoid arthritis, as well as other diseases related to vascular inflammation.
对由细胞因子和趋化因子调控的免疫过程的更深入理解，塑造了我们针对类风湿性关节炎（RA）、动脉粥样硬化和其他炎症性疾病设计治疗方法的思路。趋化因子及其受体作为炎症的重要组成部分和调节因子的发现，极大地推动了这些疾病治疗的进展。在不同类别的趋化因子中，发现具有独特功能和结构特征的fractalkine/CX3CL1参与了炎症反应。本文观点从历史、功能和临床角度总结了fractalkine/CX3CL1的新作用，并提供证据证实其作为心血管疾病、类风湿性关节炎以及其他与血管炎症相关疾病的潜在治疗靶点。
